Human Urinary Colony-stimulating Factor Research Articles

Effect of human urinary macrophage colony-stimulating factor on the immune functions and the blood cell counts in patients with ovarian carcinoma receiving cytotoxic chemotherapy.

The present study investigated the effect of macrophage colony-stimulating factor (M-CSF) on the immune functions and blood cell counts of patients with ovarian carcinoma receiving cytotoxic chemotherapy (CTX). Seventy-five consecutive patients with white blood cell counts less than 3,000/microl after CTX were randomly assigned to receive either M-CSF (human urinary macrophage colony-stimulating factor: hM-CSF, 8x106 U as 7-day intravenous infusions) or no treatment. Immune assays in addition to routine peripheral blood examinations were performed on these patients at various time points. hM-CSF dosing significantly increased monocyte, lymphocyte, granulocyte, and platelet counts that were decreased by CTX. hM-CSF also significantly enhanced lymphokine-activated killer and natural killer activities, which was accompanied by a significantly augmented interleukin (IL)-2 production. Interestingly, IL-2 production was enhanced by hM-CSF dosing in 24 of the 27 patients with a pre-hM-CSF level of IL-2 below 10 U/ml, but such an effect was not observed in nine of the 10 patients having a basal value of 10 U/ml or higher. Thus, hM-CSF is considered to be a cytokine that can augment or regulate immune functions impaired by CTX and increase blood cell counts that are decreased by CTX.

Determination of bone and fat concentrations following systemic cefamandole and regional cefuroxime administration in patients undergoing knee arthroplasty

The effect of human urinary colony-stimulating factor (CSF-HU) on in-vitro phagocytosis of Legionella pneumophila, superoxide anion production and intracellular killing of Legion, pneumophila by guinea pig alveolar macrophages was studied. Alveolar macrophages when incubated with CSF-HU demonstrated enhanced phagocytic activity and superoxide production. The bactericidal activity of treated cells was enhanced when they were afterwards incubated with a low concentration of bacteria, but these cells failed to inhibit bacterial multiplication when they were incubated with bacteria in a 1:10 ratio. In vivo, an increase in the total peripheral leucocyte count in guinea pigs after intraperitoneal injection of CSF-HU occurred and this was accompanied by an increase in granulocyte and monocyte counts. A comparison of treatment of experimental Legion, pneumophila pneumonia with CSF-HU alone, ceftazidime alone and a combination revealed lower mortality rates in the group receiving combination therapy. These data suggest a possible function for CSF-HU of enhancing antibiotic therapy in Legionnaires' disease.

Partial purification of human urinary megakaryocyte colony-stimulating factor.

Urinary extracts from patients with aplastic anemia are known to promote murine megakaryocytopoiesis. In this report, we show a simple method for the partial purification of megakaryocyte colony-stimulating factor from human urine. A four-step purification procedure, which included ethanol precipitation, CM Affi-Gel Blue chromatography, wheat germ agglutinin-Sepharose chromatography and high-resolution hydroxyapatite chromatography, resulted in an about 430- to 630-fold increase of specific activity. The final fractions were still contaminated with erythropoietin, but the contaminated content of erythropoietin was not enough to stimulate mouse megakaryocytopoiesis in our culture system. We also demonstrate that human urinary extracts stimulated human megakaryocyte colony formation.

Quantitation and Identification of Human Monocytic Colony-Stimulating Factor in Human Serum by Enzyme-Linked Immunosorbent Assay

An enzyme-linked immunosorbent assay (ELISA) system for the quantitation of human monocytic colony-stimulating factor (hM-CSF) was established, which was based on the "dual antibody immunometric sandwich" principle using horse and rabbit polyvalent antibodies against human urinary colony-stimulating factor (CSF-HU). The minimal detectable level of hM-CSF was 10 U/mL, and the assays showed good reproducibility. As measured by this method, the average serum hM-CSF level of 20 normal adults was 540 +/- 110 U/mL (range, 300 to 800 U/mL). The peak of hM-CSF measured by ELISA was identical to that measured by bioassay when semipurified CSF-HU was fractionated by reversed-phase high performance liquid chromatography (HPLC). This method detected two types of hM-CSF, which had approximate molecular weights of 85 Kd (CSF-HU) and 45 Kd in human serum and urine; the ratio of 85:45 Kd was very high in serum and the amounts of the two types were nearly equal in urine. After anticancer chemotherapy, the serum hM-CSF level of one half of the patients with hematological malignancy was elevated according to the reduction in neutrophil number, while it was almost in the normal range in the other half of the patients, indicating the possibility that anticancer chemotherapy damaged the hM-CSF-producing cells. This ELISA method may be useful for monitoring the serum hM-CSF level after anticancer chemotherapy.

Quantitation and identification of human monocytic colony-stimulating factor in human serum by enzyme-linked immunosorbent assay

An enzyme-linked immunosorbent assay (ELISA) system for the quantitation of human monocytic colony-stimulating factor (hM-CSF) was established, which was based on the “dual antibody immunometric sandwich” principle using horse and rabbit polyvalent antibodies against human urinary colony-stimulating factor (CSF-HU). The minimal detectable level of hM-CSF was 10 U/mL, and the assays showed good reproducibility. As measured by this method, the average serum hM-CSF level of 20 normal adults was 540 +/- 110 U/mL (range, 300 to 800 U/mL). The peak of hM-CSF measured by ELISA was identical to that measured by bioassay when semipurified CSF-HU was fractionated by reversed-phase high performance liquid chromatography (HPLC). This method detected two types of hM-CSF, which had approximate molecular weights of 85 Kd (CSF-HU) and 45 Kd in human serum and urine; the ratio of 85:45 Kd was very high in serum and the amounts of the two types were nearly equal in urine. After anticancer chemotherapy, the serum hM- CSF level of one half of the patients with hematological malignancy was elevated according to the reduction in neutrophil number, while it was almost in the normal range in the other half of the patients, indicating the possibility that anticancer chemotherapy damaged the hM- CSF-producing cells. This ELISA method may be useful for monitoring the serum hM-CSF level after anticancer chemotherapy.

Increases in Neutrophil Counts by Purified Human Urinary Colony-Stimulating Factor in Chronic Neutropenia of Childhood

Clinical effects of purified human urinary colony-stimulating factor (CSFHU) were studied in nine patients with chronic neutropenia of childhood who ranged in age from 1 to 18 years. The patients were given CSFHU at a dose of 6 x 10(6) U/m2/d for seven consecutive days, and their peripheral neutrophil counts were serially followed for 6 to 12 months. In addition, changes in bone marrow morphology and granulocyte-macrophage colony-forming cells (GM-CFUs) were studied. Transient increases in neutrophil counts occurred during the first 4 weeks in all patients except one. Repeated increases were seen in a cyclic fashion in five patients. Three of the patients recovered from the neutropenia after several cycles of fluctuation of neutrophil counts; the counts (per microliter) reached 5,880, 5,640, and 2,000 as compared with pretreatment levels (mean +/- 2 SD) of 80 +/- 164, 182 +/- 250, and 2 +/- 14, respectively. The percentage (mean +/- SE) of marrow neutrophilic cells increased from 30.4% +/- 7.0% to 34.9% +/- 6.9% (P less than .05) and the ratio of the later neutrophil precursors to the earlier ones from 1.02 +/- 0.27 to 1.42 +/- 0.36 (P less than .02) 2 weeks after CSFHU infusion. There were no changes in GM-CFU numbers. These results indicate that CSFHU can increase neutrophil counts by increasing the number and maturity of the marrow neutrophil precursors in some types of childhood chronic neutropenia.

Increases in neutrophil counts by purified human urinary colony- stimulating factor in chronic neutropenia of childhood

Clinical effects of purified human urinary colony-stimulating factor (CSFHU) were studied in nine patients with chronic neutropenia of childhood who ranged in age from 1 to 18 years. The patients were given CSFHU at a dose of 6 x 10(6) U/m2/d for seven consecutive days, and their peripheral neutrophil counts were serially followed for 6 to 12 months. In addition, changes in bone marrow morphology and granulocyte- macrophage colony-forming cells (GM-CFUs) were studied. Transient increases in neutrophil counts occurred during the first 4 weeks in all patients except one. Repeated increases were seen in a cyclic fashion in five patients. Three of the patients recovered from the neutropenia after several cycles of fluctuation of neutrophil counts; the counts (per microliter) reached 5,880, 5,640, and 2,000 as compared with pretreatment levels (mean +/- 2 SD) of 80 +/- 164, 182 +/- 250, and 2 +/- 14, respectively. The percentage (mean +/- SE) of marrow neutrophilic cells increased from 30.4% +/- 7.0% to 34.9% +/- 6.9% (P less than .05) and the ratio of the later neutrophil precursors to the earlier ones from 1.02 +/- 0.27 to 1.42 +/- 0.36 (P less than .02) 2 weeks after CSFHU infusion. There were no changes in GM-CFU numbers. These results indicate that CSFHU can increase neutrophil counts by increasing the number and maturity of the marrow neutrophil precursors in some types of childhood chronic neutropenia.

Characterization of deglycosylated human urinary colony-stimulating factor (CSF-1)

1. 1. Isolation of CSF-1 from human urine was performed through five purification steps. These include concentration by dialysis, silica gel absorption, hydrophobic chromatography and phenyl-Sepharose CL-6B, Fast Protein Liquid Chromatography (FPLC) and finally preparative electrophoresis on polyacrylamide gels. These methods have been reported in a previous paper (Tao et al., 1987). 2. 2. The isolated CSF-1 which exhibits a one band pattern on SDS-PAGE under non-reducing conditions after Coosmassie Blue and silver stainings, CSF-1 was purified 100,000-fold and has a specific activity of 2.16 x 10 7 units/mg protein. Its apparent M r is 57,000 with an isoelectric point pI = 5.8–6.0 CSF-l is a glycoprotein with 40% of carbohydrate (w/w). 3. 3. An almost complete removal of the carbohydrate moiety from CSF-1 was obtained after treatment with trifluoromethanesulfonic (TFMS) acid followed by gel filtration on Sephadex G-25 (Fine). The deglycosylated (DG) CSF-1 possesses an apparent M r of 38,000 and an isoelectric point, pI: 6.2 as compared to native-CSF-1 (N-CSF-1), M r = 57,000 and pI = 5.8 respectively. 4. 4. The TFMS treatment did not alter the activities of CSF-1 as shown by biological assay and receptor binding assay. The thermostability experiment revealed that DG-CSF-1 was less stable than N-CSF-1. The circular dichroism spectra (CD) of N-CSF-1 and DG-CSF-1 were different. 5. 5. The features of interaction of iodinated-N-CSF-1 and iodinated-DG-CSF-1 with single cell suspensions from human peritoneal macrophage were studied. The binding activity of peritoneal macrophage was the highest among all cells examined. The carbohydrates compositions of DG-CSF, the N-acetylglucosamine and galactosamine are established.

Isolation and characterization of human urinary colony-stimulating factor.

CSF-1 was isolated from a large volume of human normal urine (10,000 l), using the following 5 stages of purification: concentration by dialysis, silica gel adsorption, hydrophobic chromatography on phenyl-Sepharose CL-6B, fast protein liquid chromatography (FPLC) and finally preparative electrophoresis on polyacrylamide gels. We have isolated 8 mg of purified CSF-1 which migrated as a single band under non-reducing conditions in SDS-PAGE (staining with Coomassie Blue and the sensitive silver techniques). But in the presence of dithiothreitol, the SDS-PAGE pattern revealed a minor second band with a molecular mass of 50,000 Da. CSF-1 was purified 100,000-fold and has a specific activity of 2.16 X 10(7) units/mg protein. Its apparent molecular mass is 57,000 Da with an isoelectric point, pI = 5.8-6.0. The amino-acid composition is reported and compared with that of murine CSF-1. The carbohydrate content (sialic acid, sulphate groups, N-acetylglucosamine, N-acetylgalactosamine) was also determined, and it shows that CSF is a glycoprotein.

Clinical Application of Partially Purified Human Urinary Colony-Stimulating Factor

Human urinary colony-stimulating factor (CSF-HU) has been partially purified using five purification procedures (preparation II) for clinical use. In phase I study, six healthy volunteers were injected with preparation II of CSF-HU by a single intravenous droplet infusion. Two volunteers received 4 x 10 6 units (U), two received 8 x 10 6 U, and the final two received 1.2 x 10 7 U of preparation II of CSF-HU. Five volunteers did not have any symptoms, but one volunteer who received 1.2 x 10 7 U complained of transient, mild chilliness during the infusion. Liver function test, coagulation test, urine analysis and patterns of electrocardiogram did not change after infusions. In phase II study on preparation II of CSF-HU, forty-four patients with urological malignancy were infused with a daily dose of 8 x 10 6 U CSF-HU for 7 days from the next day after the end of the second courses of two consecutive courses of the same chemotherapeutic regimen. The average nadirs of leukocytes and granulocytes of 33 evaluable cases were higher in CSF-HU-infused courses (second courses) than in control courses (first courses), with statistic significances. The average period under 2,000 leukocytes/mm 3 and the average period under 500 granulocytes/mm 3 were shorter in CSF-HU-infused courses than in control courses. These results might indicate that infusions of preparation II partially protect the patients from granulocytopenia after anticancer chemotherapies.

Stimulation of haematopoiesis in primates by continuous infusion of recombinant human GM-CSF.

Certain proteins are known to play an important part in the proliferation, differentiation and functional activation of haematopoietic progenitor cells in vitro. These proteins include erythropoietin and various colony-stimulating factors (CSFs), one of which is granulocyte-macrophage colony-stimulating factor (GM-CSF). Recently, both murine and human GM-CSF have been purified to homogeneity and complementary DNAs encoding them have been cloned. Although the in vitro activity of recombinant human GM-CSF has been investigated intensively, little is known about the functional activity of this protein in vivo. There is strong evidence that colony-stimulating activities produced by various human and murine tumour tissues and cell lines can stimulate granulopoiesis in mice, as can human urinary extracts. A partially purified preparation of human urinary colony-stimulating factor, however, proved only marginally effective in stimulating granulopoiesis in humans. All these studies suffer from the lack of a homogeneous preparation of colony-stimulating factor. It has recently been shown that recombinant murine multi-CSF or interleukin-3 can stimulate haematopoiesis in mice in vivo. Large-scale production of recombinant human GM-CSF now permits us to examine its effects in vivo using a primate model. We find that the continuous infusion of GM-CSF in healthy monkeys rapidly elicits a dramatic leukocytosis and a substantial reticulocytosis. A similar effect has been observed in one pancytopenic, immunodeficient rhesus macaque. These results suggest that GM-CSF could prove useful in several clinical situations.

Biochemical properties of human urinary megakaryocyte colony-stimulating factor and erythropoietin: the role of sulfhydryl groups and disulfide bonds.

The labeling of cystine residues with [1-14C]iodoacetic acid showed that urinary preparations from patients with aplastic anemia contained 3.06 X 10(-9) mol of sulfhydryl groups and 2.90 X 10(-7) mol of half-cystine as disulfide bonds in the native state, and 6.36 X 10(-7) mol in the denatured state per absorbance unit of protein, respectively. Sulfhydryl reagent-treated proteins retained full activity of megakaryocyte colony-stimulating factor (Meg-CSF) and erythropoietin (Epo), except with DTNB-treated protein. Reduction-carboxymethylation and reduction-mercuration resulted in complete loss of Meg-CSF and Epo activities, suggesting that one of the essential chemical groups of Meg-CSF and Epo is a disulfide bond. Reduction of disulfide bonds at neutral pH revealed that Meg-CSF is less susceptible to reduction than Epo. Reactivation occurred by spontaneous reoxidation in most of the reduced Meg-CSF (92.6%) and part of the reduced Epo (22.1%). These molecular behaviors may reflect differences in the spatial configurations of Meg-CSF and Epo.

Discrepancy between the production of interleukin 1, α-interferon and granulocytic colony-stimulating activity of human monocytes stimulated by a partially purified human urinary colony-stimulating factor

A partially purified human urinary colony-stimulating factor (pp-CSF), with a specific activity of 1.0 × 10 6 U/mg protein, was purified by using a stepwise DEAE-cellulose anion exchange chromatography and a molecular sieve high performance liquid chromatography (TSK gel G3000SW) sequentially. Production of three kinds of monokines by human peripheral blood monocytes was tested in vitro, which contained granulocytic colony-stimulating activity (G-CSA), interleukin 1 (IL-1) and intefferon α(IFN-α). Human peripheral blood mononuclear cells were separated by Ficoll-Hypaque density gradient centrifugation, and monocytes were obtained by adherence to dishes. Although pp-CSF stimulated monocytes to produce G-CSA in vitro, it failed to stimulate the IL-1 or IFN-α production. The discrepancy between production or release of these three kinds of monokines by human monocytes stimulated with pp-CSF suggests that pp-CSF preferentially stimulates human monocytes to produce G-CSA. To test the effects of pp-CSF on human monocytes in vivo, we performed i.v. infusions of pp-CSF to four volunteers, and we then took peripheral blood monocytes. Compared to before the infusion of pp-CSF, G-CSA production by monocytes was enhanced, while production of IL-1 and IFN-α was not enhanced after the infusion of pp-CSF. These results suggest that pp-CSF stimulates monocytes to produce G-CSA but not to produce IL-1 nor IFN-α.

Purification of human urinary colony-stimulating factor by high-performance liquid chromatography

Purification of human urinary colony-stimulating factor by high-performance liquid chromatography

Regulatory Mechanism of Granulopoiesis in the Bone Marrow of CSF-Producing Tumor-Bearing Nude Mice

Abstract The regulatory mechanism of differentiation of granulocyte and macrophage precursor cells (G/M CFU-C) in bone marrow and spleen obtained from nude mice bearing colony-stimulating factor (CSF) producing tumor (G-mice), which developed marked granulocytosis, was studied. In these mice, granulopoiesis is enhanced in the spleen, but suppressed in bone marrow. Coculture of G-mouse bone marrow cells with splenic cells of control nude mice (C-mice) and of G-mice resulted in 68% and 62%, respectively, more colonies than expected, while coculture of C-mouse bone marrow cells with these two sources of cell fractions resulted in only 2% and 11% more colonies. In the double-layer agar culture system, bone marrow and splenic cells of C- and G-mice produced a maximal number of colonies containing adequate amounts of human urinary CSF in the upper layer when C-mouse bone marrow cells were added to the lower layer, while these four sources of cells produced a moderate or minimal number of colonies when splenic cells of C- and G- mice or G-mouse bone marrow cells were added to the lower layer. Morphological examination of colonies formed in the upper layer revealed that addition of C-mouse bone marrow cells or irradiated G- mouse bone marrow cells to the lower layer resulted in a massive increment in the number of colonies with pure granulocytes and granulocyte and macrophage mixed (G + G/M) colonies formed by G-mouse bone marrow cells in the upper layer. However, the addition of irradiated C-mouse bone marrow cells or G-mouse bone marrow cells before irradiation to the lower layer did not change G + G/M colony formation by G-mouse bone marrow cells in the upper layer. We could reproduce these findings with conditioned media obtained from 3-day liquid cultures of these cell fractions. This suggests that a diffusible factor may be necessary for inhibition of G + G/M colony formation in G-mouse bone marrow cells. The fine mechanism of such inhibition remains to be clarified.

Regulatory mechanism of granulopoiesis in the bone marrow of CSF- producing tumor-bearing nude mice

The regulatory mechanism of differentiation of granulocyte and macrophage precursor cells (G/M CFU-C) in bone marrow and spleen obtained from nude mice bearing colony-stimulating factor (CSF) producing tumor (G-mice), which developed marked granulocytosis, was studied. In these mice, granulopoiesis is enhanced in the spleen, but suppressed in bone marrow. Coculture of G-mouse bone marrow cells with splenic cells of control nude mice (C-mice) and of G-mice resulted in 68% and 62%, respectively, more colonies than expected, while coculture of C-mouse bone marrow cells with these two sources of cell fractions resulted in only 2% and 11% more colonies. In the double-layer agar culture system, bone marrow and splenic cells of C- and G-mice produced a maximal number of colonies containing adequate amounts of human urinary CSF in the upper layer when C-mouse bone marrow cells were added to the lower layer, while these four sources of cells produced a moderate or minimal number of colonies when splenic cells of C- and G-mice or G-mouse bone marrow cells were added to the lower layer. Morphological examination of colonies formed in the upper layer revealed that addition of C-mouse bone marrow cells or irradiated G-mouse bone marrow cells to the lower layer resulted in a massive increment in the number of colonies with pure granulocytes and granulocyte and macrophage mixed (G + G/M) colonies formed by G-mouse bone marrow cells in the upper layer. However, the addition of irradiated C-mouse bone marrow cells or G-mouse bone marrow cells before irradiation to the lower layer did not change G + G/M colony formation by G-mouse bone marrow cells in the upper layer. We could reproduce these findings with conditioned media obtained from 3-day liquid cultures of these cell fractions. This suggests that a diffusible factor may be necessary for inhibition of G + G/M colony formation in G-mouse bone marrow cells. The fine mechanism of such inhibition remains to be clarified.

High Serum Colony-Stimulating Activity of Leukocytopenic Patients After Intravenous Infusions of Human Urinary Colony-Stimulating Factor

Eight adult patients suffering from leukocytopenia have been injected by droplet intravenous infusions with partially purified human urinary colony-stimulating factor (CSFHU), which stimulated human monocytes to produce colony-stimulating activity (CSA) in vitro. Three of eight patients were injected with low-dose CSFHU and five with high-dose CSFHU. The infusion of high-dose CSFHU led to a slightly earlier rise in absolute neutrophil counts and a higher CSA level in the serum, as compared to noninjected leukocytopenic patients. There was little toxicity associated with it. Human urinary colony-stimulating factor used in the clinical studies did not have any CSA in vitro in the presence or absence of the patients' sera. These data may suggest that the intravenous infusion of CSFHU increased the serum CSA level, probably through the stimulation of CSA-producing cells in vivo.

High serum colony-stimulating activity of leukocytopenic patients after intravenous infusions of human urinary colony-stimulating factor

Eight adult patients suffering from leukocytopenia have been injected by droplet intravenous infusions with partially purified human urinary colony-stimulating factor (CSFHU), which stimulated human monocytes to produce colony-stimulating activity (CSA) in vitro. Three of eight patients were injected with low-dose CSFHU and five with high-dose CSFHU. The infusion of high-dose CSFHU led to a slightly earlier rise in absolute neutrophil counts and a higher CSA level in the serum, as compared to noninjected leukocytopenic patients. There was little toxicity associated with it. Human urinary colony-stimulating factor used in the clinical studies did not have any CSA in vitro in the presence or absence of the patients' sera. These data may suggest that the intravenous infusion of CSFHU increased the serum CSA level, probably through the stimulation of CSA-producing cells in vivo.

Granulocyte-macrophage colony-stimulating and binding activities of purified human urinary colony-stimulating factor to murine and human bone marrow cells

Granulocyte-macrophage colony-stimulating and binding activities of purified human urinary colony-stimulating factor to murine and human bone marrow cells

Granulocyte-macrophage colony-stimulating and binding activities of purified human urinary colony-stimulating factor to murine and human bone marrow cells

Granulocyte-macrophage colony-stimulating and binding activities of purified human urinary colony-stimulating factor to murine and human bone marrow cells